Tag: venovalve
First-in-human patients continue to benefit from VenoValve at average of three...
Positive long-term, three-year observational data from a cohort of patients that participated in the previously concluded VenoValve (Envveno Medical) first-in-human clinical trial were recently...
AVF 2022: VenoValve improvement “maintained” for 2.5 years without adverse events
Envveno Medical announced positive 30-month data from the first-in-human trial of the VenoValve bioprosthetic potential venous valve replacement during the 2022 American Venous Forum...
Envveno Medical reports successful completion of first VenoValve surgery for US...
Envveno Medical, formerly Hancock Jaffe Laboratories, recently announced that the first VenoValve surgery in the company’s SAVVE US pivotal trial for the VenoValve has...
“The future is very bright for venous valve replacement”
The progress of two “promising” new devices in the venous valve replacement space were outlined during a special session at the Society for Vascular...
Hancock Jaffe presents positive two-year VenoValve data at SVS VAM 2021
Hancock Jaffe Laboratories has announced that promising two-year post-VenoValve implantation data are being presented today at the Society for Vascular Surgery’s Vascular Annual Meeting...
FDA grants Breakthrough Device designation status for Hancock Jaffe’s VenoValve
Hancock Jaffe Laboratories today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device designation status to the VenoValve, the company’s...
First US patent issues on Hancock Jaffe VenoValve
Hancock Jaffe Laboratories has revealed that the United States Patent and Trademark Office (USPTO) has issued the first patent covering the company's VenoValve. The...
Hancock Jaffe receives IDE approval to begin VenoValve US pivotal trial
Hancock Jaffe Laboratories recently announced that the US Food and Drug Administration (FDA) has approved the company's Investigational Device Exemption (IDE) application to begin...
Hancock Jaffe, maker of the VenoValve, completes US$41 million public offering
Hancock Jaffe Laboratories recently announced that it has completed a public offering of its securities, generating approximately US$41.4 million of gross proceeds, prior to...
Initial results from first-in-man trial of prosthetic VenoValve demonstrate promise
Initial results of an ongoing first-in-man study in Colombia, that saw the implantation of a prosthetic venous valve in 15 patients, have demonstrated an...
Endpoints for first-in-human VenoValve study announced by Hancock Jaffe
Medical device company Hancock Jaffe has announced the end-points for its upcoming VenoValve first-in-human study in Bogota, Colombia. Endpoints for the study will include...
Medical research committee gives approval for first-in-man VenoValve study
Hancock Jaffe Laboratories, a company specialising in bioprosthetic medical devices for treating cardiac and vascular diseases, has received approval for the first-in-man testing of...